Fig. 7 |. Single-dose alum/IL12 therapy enhances intratumoural T and NKT cell activity.

a, Overall survival for mice bearing B16F10 tumours treated as in Fig. 3c that were also administered depleting antibodies starting 1 day before treatment and every 3d thereafter (untreated n=10 mice/group, treated n=23 mice/group, treated + anti-CD8α n = 12 mice/group, and treated + anti-NK1.1 n=7 mice per group). b-h, Mice bearing B16F10 tumours (n=5 mice per group) were treated as in Fig. 6a. Tumours were analyzed on days 3, 6 and 9 after treatment by flow cytometry. Shown are the quantification of tumour-infiltrating CD8⁺ T, NK and NKT cells (mean ± SD, b), granzyme B geometric MFI (c), representative flow plots for intratumoural CD8⁺ T cells (d), and enumeration (mean ± SD) of intratumoural IFN-γ⁺granzyme B⁺ CD8⁺ T and NKT cells (e) on day 3. f, Ratio of CD8⁺ T cell counts to FoxP3⁺CD25⁺ Treg counts over time (mean ± SD). g-h, Representative day 3 flow plots (g) and quantification (mean ± SD, h) of CD25 expression by intratumoural CD8⁺ T cells. ABP refers specifically to ABP10. P values were determined by the log-rank (Mantel-Cox) test (a) and one-way (c,e) or two-way (f,h) ANOVA followed by Tukey’s multiple comparison test using GraphPad PRISM. ns, not significant or P > 0.05.